Nov 17, 2025 · Avalo is a clinical-stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, …

At Avalo, we’re 100% focused on developing treatments for immune-mediated inflammatory diseases with large unmet needs that affect millions worldwide. Our strategy is to develop …

Progressing product candidates targeting immune-mediated inflammatory diseases We are advancing a pipeline that emphasizes a high-value, potentially best-in-class and best-in …

Nov 6, 2025 · Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, …

Jun 23, 2025 · Oct 29, 2025 7:00 am EDT Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Oct 8, 2024 · Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, …

Jun 30, 2025 · Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead …

Mar 27, 2024 · Avalo’s current leadership team will continue to lead Avalo and no person affiliated with AlmataBio will become an officer or employee of Avalo. Pursuant to the acquisition, …

At Avalo, our mission is to transform lives with novel therapeutics targeting immune-mediated inflammatory diseases that realize the promise of best-in-class and best-in-disease medicines.

Rusty the Cavapoo is wagging his way up the corporate ladder at Avalo. He joined the company as Mascot in 2022 and, given his impressive in-office accomplishments, his recent promotion …